Assess whether scientific advice should be sought before the next trial

Situation

After a DSMB note on an imbalance that is not yet a signal, RWE protocol that may not meet regulator expectations is what clinical-development physician can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

Decision

Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• RWE protocol that may not meet regulator expectations reads as Proceed under protocol once a DSMB note on an imbalance that is not yet a signal is lined up to the same Pharma & Life Sciences population.
• RWE protocol that may not meet regulator expectations is closer to Pause the pathway after a DSMB note on an imbalance that is not yet a signal; Proceed under protocol would over-claim this Pharmacovigilance extract.
• Escalate safety review is still live in RWE protocol that may not meet regulator expectations for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.
• RWE protocol that may not meet regulator expectations is missing the fact clinical-development physician needs after a DSMB note on an imbalance that is not yet a signal; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move scientific advice should be for clinical-development physician.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.